US12285417 — Methods for treating chronic obstructive pulmonary disease
Method of Use · Assigned to Thera Vance Biopharma R&d Ip LLC · Expires 2039-08-29 · 13y remaining
What this patent protects
This patent discloses methods for treating chronic obstructive pulmonary disease (COPD) in patients selected based on their peak inspiratory flow rate and percent predicted FEV1.
USPTO Abstract
Methods for treating chronic obstructive pulmonary disease (COPD) in a patient are disclosed. In the methods, a patient having COPD is selected for treatment based on the patient's peak inspiratory flow rate (PIFR) and percent predicted force expiratory volume in one second (FEV 1 ); and a bronchodilator is administered to the selected patient using a nebulizer. Administration of a bronchodilator to patients having low PIFR and a percent predicted FEV 1 less than 50 percent using a nebulizer as the inhalation delivery device provides significantly greater improvements in trough FEV 1 and trough forced vital capacity (FVC) compared to administration of a bronchodilator to such patients using a dry powder inhaler.
Drugs covered by this patent
- Yupelri (REVEFENACIN) · Mylan Ireland Ltd
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-2440 |
— | Yupelri |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.